Sodium-glucose co-transporter-2 (SGLT2) inhibitors reduce heart failure hospitalisations by more than a third and halve all-cause mortality compared to other glucose-lowering treatments in type 2 diabetes, according to new research presented at the American College of Cardiology’s meeting in Washington.

Sponsor AstraZeneca says the study is “the first large real-world evidence study of its kind” comparing SGLT-2 inhibitors and other type 2 diabetes medicines.

The study used databases from six countries (the US, Norway, Denmark, Sweden, Germany and the UK) to match 154,523 type 2 diabetes patients taking SGLT-2 inhibitors (dapagliflozin, canagliflozin, empagliflozin) with the same number of controls taking other glucose-lowering drugs.

Most patients (87 per cent) did not have a history of cardiovascular disease. There were 961 hospitalisations for heart failure across the six countries. The German database did not yield linked mortality but in the remaining five countries, 1,334 of 215,622 patients died.

Treatment with a SGLT-2 inhibitor reduced hospital-isations for heart failure by 39 per cent (hazard ratio [HR] 0.61) and deaths from any cause by 51 per cent (HR 0.49) compared with other type 2 diabetes medicines. SGLT-2 inhibitors reduced the composite of heart failure hospitalisation or death from any cause by 46 per cent. There was no significant difference by country.

The study did not examine other cardiovascular events, such as myocardial infarction and stroke, or focus on safety. Moreover, the authors also note that experience with SGLT-2 inhibitors “in real-world practice is still relatively short”. Longer-term follow-up is therefore needed to determine whether the benefits are sustained.

Recommended

Obesity increases RA risk in women

A study presented at the European Congress of Rheumatology has shown that obese women have a higher RA risk

Aspirin may protect against breast cancer in diabetes

Long-term low-dose aspirin reduces the risk of breast cancer in women with diabetes

Popular

Achieving Excellence welcomed by profession

Pharmacy bodies give thumbs up to Scotland’s latest strategy for the profession with its focus firmly on pharmaceutica...

EHC row: value and price are not the same thing

By Pharmacy Magazine editor, Richard Thomas. The row over the cost of EHC from pharmacies – and the overwrought tone o...

Mike Smith celebrates 50 years in pharmacy

Pharmacy grandee Mike Smith is celebrating 50 years in the profession this year. “I can’t believe it”, he says